Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

Cancer

Volumn 115, Issue 9, 2009, Pages 1906-1913

  Luminari, Stefano ^a   Marcheselli, Luigi ^a   Sacchi, Stefano ^a   Pozzi, Sacchi Samantha ^a   Bari, Alessia ^a   Llariucci, Fiorella ^b   Stelitano, Caterina ^c   Angrilli, Francesco ^d   Lazzaro, Antonio ^e   Baldini, Luca ^f  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Reggio Emilia Hospital   (Italy)

^c Ospedale di Reggio Calabria   (Italy)

^d Pescara Hospital   (Italy)

^e Hospital of Piacenza   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Anthracycline; Fludarabine; Follicular lymphoma; Non hodgkin lymphoma; Rituximab

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP B PROTOCOL; CHOP-B PROTOCOL; DOXORUBICIN; DRUG DERIVATIVE; FND PROTOCOL; MONOCLONAL ANTIBODY; VIDARABINE;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BRONCHOPNEUMONIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN TISSUE; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REMISSION; THROMBOCYTOPENIA; GENETICS; MIDDLE AGED; PROTO ONCOGENE; SURVIVAL;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; GENES, BCL-2; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; VIDARABINE; VINCRISTINE;

EID: 65749118604     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24222     Document Type: Article

References (20)

1. Aurora V. Winter JN. Current controversies in follicular lymphoma. Blood Rev. 2006;20:179-200. (Pubitemid 44250958)
2. Meijerink JP.t (14;18), a journey to eternity. Leukemia. 1997;11:2175-2187.
3. Gallagher C. J. Gregory W. M. Jones A. E. et al. Follicular lymphoma; prognostic factors for response and survival. J Clin Oncol 1986;14:1470-1480. (Pubitemid 17183570)
4. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas, Semin Oncol. 1993;9:669-687 (Pubitemid 23319044)
5. Sacchi S. Marcheselli L. Bari L. et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer, 2007;109:2077-2082. (Pubitemid 46744202)
6. Czuczman M. S. Weaver R. Alkuzweny B. et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711-4716. (Pubitemid 41185080)
7. Sacchi S. Pozzi S. Marcheselli R. et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer. 2007;110:121-128. (Pubitemid 46992032)
8. Demann W. Kneba M. Dreyling M. et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:13725-3732. (Pubitemid 46211378)
9. van Oers M. H. Klasa R. Marcus R. E. et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood, 2006108:3295-3301.
10. Forstpointner R. Dreyling M. Repp R. et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mande cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064-3071. (Pubitemid 39517009)
11. McLaughlin P. Rodriguez M. A. Hagemeister F. B. et al. Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND (fludarabine, mitoxantrone, dexamethasone) chemotherapy and rituximab monoclonal antibody therapy, with interferon maintenance [abstract]. J. Clin Oncol 2003;22;564. Abstract 2269.
12. Herold M. Pasold R. Srock S. et al. Result of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantlecell-lymphoma (MCL) [abstract]. Blood. 2004; 104; 169a. Abstract 584.
13. Marcus R. Imrie K. Belch A. et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423. (Pubitemid 40223656)
14. Kaplan E. L. Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:1457-481.
15. Mantel N. Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease.J Natl Cancer Inst. 1959;22:719-748.
16. Cox D. Regression models and life tables.J R Stat Soc B. 1972;34:187-202.
17. Armitage P. Berry G. Statistical Method in Medical Research. 2nd ed. Oxford, UK: Blackwell Scientific Publications; 1987. (Pubitemid 18039179)
18. Solal-Celigny P. Roy P. Colombat P. et al. Follicular lymphoma prognostic index. 1Blood. 2004;104:1258-1265.
19. Rambaldi A. Lazzari M. Manzoni C. et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99:856-862. (Pubitemid 34525546)
20. +cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood. 2005;9:3428-3433. (Pubitemid 40628182)